Please login to the form below

Not currently logged in

AbbVie submits Parkinson’s disease therapy to FDA

The therapy offers a first-of-its-kind, 24-hour, continuous subcutaneous delivery


AbbVie has submitted a new drug therapy, ABBV-951, to the US Food and Drug Administration (FDA) for patients with advanced Parkinson's disease.

The therapy – which is also known as foscarbidopa/foslevodopa – focuses on motor fluctuations.

The submission is based on results from a phase 3, head-to-head, randomised and controlled clinical trial which demonstrated statistically significant improvement among patients.

Approximately 130 adult participants with Parkinson's, whose motor symptoms were no longer adequately controlled by their current medications, were enrolled in the study at 80 sites in the US and Australia.

ABBV-951 is designed to provide a first-of-its-kind, 24-hour, continuous subcutaneous delivery of carbidopa/levodopa (CD/LD). Compared to oral CD/LD, it offers the potential for improvement in motor fluctuations in patients with advanced Parkinson's.

Adverse events during the trial were non-serious, mild or moderate. There were no deaths in the ABBV-951 group, while in the oral CD/LD group, one patient died as a result of a treatment-emergent adverse event.

The most common adverse events reported – in fewer than 10% of patients in the ABBV-951 group – were erythema, pain, cellulitis, edema and dyskinesia.

The submission is also supported by results from an ongoing multi-centre, phase 3, open-label study, which is assessing the long-term safety and efficacy of the therapy.

"Advanced Parkinson's disease causes unrelenting challenges and uncertainty for patients and caregivers worldwide," said Thomas Hudson, senior vice president, research and development at AbbVie.

"We are committed to addressing the unmet needs of those affected by the disease and recognise the urgency for a new treatment that can enable better symptom control through the continuous 24-hour administration of medication."

Parkinson's disease is a progressive and chronic neurological disorder resulting from the loss of dopamine-producing brain cells that primarily manifests itself with tremors, muscle rigidity, slowness of movement and balance difficulty.

Patients and their healthcare providers typically share the same goal – to extend the amount of ‘on’ time – the period when symptoms are well controlled without involuntary movements.

AbbVie will continue to pursue regulatory submissions for ABBV-951 in several international markets throughout the year.

Article by
John Pinching

24th May 2022

From: Research, Regulatory, Healthcare



Subscribe to our email news alerts

Featured jobs


Add my company
Jet Off with Maloff Protect

Latest intelligence

Virtual MSL/Sales training programs and events
Top 10 ways to leverage the Impetus InSite Platform® for internal MSL/Sales training programs and events...
6 trends shaping the future of personalized medicine
Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....
Omnichannel strategies to revolutionize the healthcare professional experience
Fishawack Health’s omnichannel experts unite to reveal how medical and commercial teams can build more meaningful experiences for healthcare professionals. They discuss the opportunities of omnichannel and explore how the...